Bispecific Antibody Format Design Series

Mechanism-Driven Bispecific Format Design

Format selection directly determines how the mechanism performs in vivo within different bispecific antibody formats.

The illustration below (Herrera M, et al. 2024) provides representative examples of how different bispecific formats operate across major therapeutic mechanisms. It highlights immune cell-redirecting formats such as a bispecific T cell engager, immune checkpoint modulation strategies, and dual-target signaling blockade approaches, demonstrating how bispecific antibody design aligns structural architecture with functional intent. These examples reinforce that molecular architecture must be tailored to the specific biological context in which the bispecific is expected to act, underscoring the importance of disciplined bispecific antibody engineering.

Target biology and mechanism of action should dictate molecular architecture, such as:

• A bispecific format that bridges two membrane proteins on opposing cells must account for epitope distance, intercellular spacing, and valency.
• A molecule coordinating soluble factors in circulation has different geometric requirements.
• Dual receptor blockade may require balanced affinities and preserved Fc functions.
• Targeting two distinct epitopes on the same antigen to enhance functional blockade, internalization, and resistance control.
• Valency (1+1, 2+1, 2+2), domain orientation, and molecular size influence receptor clustering, signaling strength, and tissue penetration.
• Effector module design, including Fc isotype selection, Fc silencing or enhancement, determines engagement of Fcγ receptors and complement pathways, shaping ADCC, ADCP, or CDC activity.

Tissue Penetration Considerations

Smaller fragment-based formats, such as tandem scFv constructs, may achieve deeper tissue access due to reduced steric bulk. In some cases, additional tissue-targeting arms or increased valency are introduced during bispecific antibody design to enhance local retention and functional engagement.

Central nervous system delivery presents distinct constraints, as transport across the blood-brain-barrier (BBB) relies on receptor-mediated transcytosis rather than passive diffusion, making architecture and targeting strategy critical. (Faresjö R et al, 2021)

However, compact and tandem structures often lack an Fc region, leading to rapid systemic clearance. They may also carry higher aggregation risk, which can further accelerate clearance. Improved penetration must therefore be balanced against stability and exposure durability.

To preserve tissue access while enhancing PK and stability, strategies such as Fc or albumin-binding fusion, half-life extension modules, optimized valency design, and stability engineering (e.g., disulfide reinforcement or interface optimization) can be incorporated early in bispecific antibody design.

Clinical Examples: Geometry and PK Trade-offs in T Cell Engagers

Few modalities illustrate mechanism-driven format selection as clearly as T cell engagers (TCEs). In these molecules, physical distance between a T cell and a tumor cell directly determines cytotoxic efficiency. The bispecific antibody must simultaneously bind CD3 on the T cell and a tumor-associated antigen, bringing the two cells into proximity to form an effective immunological synapse.

When the tumor epitope is located far from the cell membrane, a large IgG-like molecule may create excessive spacing between the two cells. This increased distance can reduce T cell activation efficiency. In such cases, a compact fragment-based format may better support cytolytic synapse formation. Conversely, when PK durability and dosing convenience are critical, IgG-like formats may be favored despite their larger size.

Blinatumomab: Potency Through Compact Space

Blinatumomab exemplifies a potency-driven, space-optimized design. It is a tandem single-chain variable fragment (BiTE) construct without an Fc domain. Its compact structure allows efficient immune synapse formation between CD19-positive B cells and CD3-positive T cells, driving strong cytotoxic activity. (Aureli A et al., 2023)

However, the absence of an Fc region eliminates FcRn-mediated recycling. As a result, blinatumomab has a short systemic half-life and requires continuous intravenous infusion. The format maximizes functional proximity and activation efficiency but sacrifices pharmacokinetic durability.

This example highlights a central trade-off in bsAb design: maximizing biological potency may impose constraints on exposure profile and dosing convenience.

While biological mechanism and molecular architecture determine whether a bispecific antibody can achieve its intended function, successful programs must also ensure that the selected format can be produced, screened, and characterized reliably during discovery.

In the next article of this series, we will examine how pharmacokinetics and biophysical considerations shape practical bispecific format selection and support efficient discovery-stage engineering.

Follow us on LinkedIn to receive notifications when the next article in this series is published, along with additional insights on bispecific antibody discovery and development.